🇺🇸 FDA
Pipeline program

Baxdrostat, Baxdrostat Placebo

Bax24 / D6970C00009

Phase 3 small_molecule active

Quick answer

Baxdrostat, Baxdrostat Placebo for Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials